Industry update tracker: October 2026
A monthly index of company press releases and announcements shaping the real-world data (RWD), real-world evidence (RWE) and health technology assessment (HTA) landscape, looking at the latest developments from October 2026.
Briya Appoints CCO Jason Hein to Bring AI-Native Evidence Generation to Global Research Organizations and Life Sciences
Briya, developer of AIRE, the scientific AI platform turning fragmented healthcare data into defensible evidence, today announced the appointment of Jason Hein as Chief Commercial Officer. The hire marks the beginning of a deliberate scale-up phase for the company, as Briya moves from proving AIRE's value with early research partners to expanding across the organizations that generate RWE for life sciences worldwide.
Cardinal Health Real-World Data and Evidence and Eli Lilly and Company launch study to improve IBD care
Cardinal Health Real-World Data and Evidence, in collaboration with Eli Lilly and Company, has launched a study called INSIGHT-IBD leveraging its Specialty Networks Research Network of community gastroenterology practices. This RWE study will leverage first-party electronic health records, prospective data collection and patient surveys to capture a long-term picture of what IBD patient care looks like outside of a clinical trial.
Colait Launches Neuroscience Data Collection Initiative, Advancing the Case for Clinical Opinion as a Core Layer of Real-World Evidence
Colait announced the launch of a structured clinical opinion data collection initiative in neuroscience, marking the company's first large-scale therapeutic area study and a significant expansion of what will become the first nationally representative qualitative clinical opinion dataset across therapy areas.
EVERSANA and Pulse Infoframe Announce Strategic Partnership to Deliver Global Real-World Evidence and HEOR Solutions
EVERSANA, a leading provider of technology enabled, modern commercialization services to the biopharmaceutical industry, announced a strategic partnership with Pulse Infoframe, a leader in RWE generation and intelligence. Through the partnership, EVERSANA will pair its end-to-end commercialization, market access and HEOR expertise with Pulse Infoframe’s proprietary RWE platform and established evidence-generation capabilities, creating a single, continuous evidence engine for pharmaceutical and medical device companies.
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of UK-based Estima Scientific
EVERSANA also announced the acquisition of Estima Scientific, an innovative, London-based health economics and outcomes research (HEOR) technology and services company. Estima Scientific will integrate its specialty consulting expertise and proprietary software into EVERSANA's market access and value & evidence solutions to help pharmaceutical companies demonstrate a drug's clinical and economic value more efficiently and transparently to payers.
Genesis Research Group Appoints Vera Frajzyngier to Lead Global Real-World Evidence Business
Genesis Research Group has appointed Vera Frajzyngier, PhD, Vice President and Head of RWE, bringing more than 20 years of experience in epidemiology, pharmaceutical research and regulatory evidence generation to its global scientific leadership team. Frajzyngier will oversee Genesis Research Group’s global RWE business, leading the development and delivery of evidence strategies supporting pharmaceutical product development, regulatory decision-making, market access and commercialization.
Flatiron Health Expands Telescope to International Real-World Data, Bringing AI-Powered Oncology Insights to a Global Database of More Than Six Million Patients
Flatiron Health announced the international expansion of Flatiron Telescope, its AI-powered oncology intelligence platform, extending its capabilities to datasets from the UK, Germany, and Japan. Building on Telescope’s launch earlier this year, the expansion brings a global dimension to how life sciences teams ask and answer oncology questions, drawing on Flatiron’s real-world database of more than six million patients.
Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation
Oracle announced an agreement with AstraZeneca to explore how AI and RWD can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring relevant research insights into everyday care. The collaboration is expected to combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data, cloud, AI, analytics, and clinical workflow capabilities.
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
PacBio, developer of the world’s most advanced sequencing technologies, and Verily Health Inc., a healthcare data intelligence company, announced today a multi-year strategic collaboration to integrate PacBio HiFi sequencing with Verily Health’s governed data and AI platform. The collaboration will link PacBio sequencing workflows to Verily Pre, combining long-read genomic data with real-world clinical data at population scale. The resulting AI-ready clinico-genomic datasets will support biomedical discovery efforts and AI model training and deployment.
Petauri Expands HEOR and Market Access Capabilities with Acquisition of Franklin Pharmaceutical Consulting
Petauri, a purpose-built pharmaceutical services platform, today announced the acquisition of Franklin Pharmaceutical Consulting (FPC), a specialized HEOR, RWE, and market access consultancy. The acquisition strengthens Petauri's ability to support life sciences companies in generating evidence, communicating product value, and navigating complex access and reimbursement decisions.
Verana Health and Bitfount Collaborate to Simplify Prescreening for Ophthalmic Clinical Trials
Verana Health® has announced a new partnership with Bitfount, an on-premise federated AI analysis platform. The collaboration aims to significantly improve and accelerate patient identification for ophthalmology clinical studies.
By combining ophthalmic imaging with electronic health record data, this joint solution enables faster, more accurate patient prescreening. The approach was recently clinically validated in a study with Moorfields Eye Hospital.
| Register for free today to become a member of The Evidence Base and receive the latest news straight to your inbox. |